The shared phenotypes of aripiprazole and mice with impaired LEP/LEPR function like “obesity”, “insulin resistance” and “glucose tolerance impaired” (Fig 3a) point to alterations of leptinergic signalling by the antipsychotic aripiprazole. Here, LEPR is linked to obesity disorder.